GEMINI-C: First Line Treatment for Patients with an Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Condition: Gastric or Gastroesophageal Junction Cancer
Sponsor: AstraZeneca
Full Title
D7986C00001: A Master Protocol of an Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Novel Combinations in Participants with Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Study Treatment
Eligible patients will be treated with one of the following treatment regimens: Substudy 1 MEDI5752 in combination with FOLFOX or XELOX Substudy 2 AZD2936 in combination with FOLFOX or XELOX
MEDI5752 is a PD-1/CTLA-4 targeting bispecific antibody
AZD2936 is a PD-1/TIGIT targeting bispecific antibody
Eligibility/Info
For the first line treatment of patients with advanced or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma
Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
